Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were observed in ageing‐related biomarkers (IGF‐1, vitamin D) or most inflammatory markers, except for a trend towards higher hsCRP levels (Table S5).

Source: Association of Muscle‐Specific Strength With Biomarkers. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I‐Lan Longitudinal Aging Study.

Source: Abstract.

Participants were categorized into low and normal MSS groups using age‐sex‐specific cutoffs based on quintiles.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Cohort study · Journal of Cachexia, Sarcopenia and Muscle · 2025

Original publication title

Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Wen‐Kai Chien; Wei‐Ju Lee; Chih‐Kuang Liang; Ko‐Han Yen; Li‐Ning Peng; Ming‐Hsien Lin; Ching‐Hui Loh; Fei‐Yuan Hsiao; Liang‐Kung Chen

© 2025 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Muscle‐specific strength (MSS), defined as grip strength normalized to arm muscle mass, may better reflect muscle efficiency than grip strength. Despite its potential utility in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia‐related outcomes remain limited. This study investigated the associations of MSS with physical performance deterioration and biomarker profiles in community‐dwelling older adults, compared it with conventional measures, determined whether MSS‐defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examined associations with key cardiometabolic and inflammatory biomarkers.

Source: Background

Abstract: What methods does the paper describe?

This prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I‐Lan Longitudinal Aging Study. MSS was calculated by dividing handgrip strength by dominant arm muscle mass. Participants were categorized into low and normal MSS groups using age‐sex‐specific cutoffs based on quintiles. Physical function was assessed using the five‐time chair stand test, with impaired physical performance (PPI) defined as taking ≥ 12 s. Logistic regression models examined the associations between MSS and PPI, adjusted for demographics, comorbidities, cognitive function and skeletal muscle index.

Biomarker profiles, including metabolic, inflammatory and hormonal parameters, were compared across MSS groups.

Source: Methods

Abstract: Results

Low MSS was found in 19.9% of participants. Those with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 vs. 7.1 ± 1.2 kg/m2, p < 0.001; dominant hand muscle mass, 2.7 ± 0.8 vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size. PPI was more common in the low MSS group (47.8% vs. 29.0%, p < 0.001).

Low MSS was significantly associated with higher odds of PPI (adjusted OR = 1.49, 95% CI: 1.11 to 1.99, p = 0.008), particularly among participants aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and males (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018). MSS‐defined sarcopenia showed a stronger association with PPI (OR = 3.31, 95% CI: 1.26 to 8.74, p = 0.015) than conventional sarcopenia definitions. Individuals with low MSS demonstrated adverse metabolic profiles, including higher fasting glucose (101.0 ± 27.3 vs. 95.0 ± 18.7 mg/dL, p < 0.001), HbA1c (6.0% ± 0.9% vs. 5.8% ± 0.7%, p < 0.001) and HOMA‐IR (2.6 ± 2.2 vs. 1.8 ± 1.4, p < 0.001).

In adjusted models, high HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001) and elevated hsCRP (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.001) were strongly associated with low MSS.

Source: Results

Abstract: Conclusions

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Muscle‐specific strength (MSS), defined as grip strength normalized to arm muscle mass, may better reflect muscle efficiency than grip strength. Despite its potential utility in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia‐related outcomes remain limited. This study investigated the associations of MSS with physical performance deterioration and biomarker profiles in community‐dwelling older adults, compared it with conventional measures, determined whether MSS‐defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examined associations with key cardiometabolic and inflammatory biomarkers.

Methods

This prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I‐Lan Longitudinal Aging Study. MSS was calculated by dividing handgrip strength by dominant arm muscle mass. Participants were categorized into low and normal MSS groups using age‐sex‐specific cutoffs based on quintiles. Physical function was assessed using the five‐time chair stand test, with impaired physical performance (PPI) defined as taking ≥ 12 s. Logistic regression models examined the associations between MSS and PPI, adjusted for demographics, comorbidities, cognitive function and skeletal muscle index.

Biomarker profiles, including metabolic, inflammatory and hormonal parameters, were compared across MSS groups.

Results

Low MSS was found in 19.9% of participants. Those with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 vs. 7.1 ± 1.2 kg/m2, p < 0.001; dominant hand muscle mass, 2.7 ± 0.8 vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size. PPI was more common in the low MSS group (47.8% vs. 29.0%, p < 0.001).

Low MSS was significantly associated with higher odds of PPI (adjusted OR = 1.49, 95% CI: 1.11 to 1.99, p = 0.008), particularly among participants aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and males (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018). MSS‐defined sarcopenia showed a stronger association with PPI (OR = 3.31, 95% CI: 1.26 to 8.74, p = 0.015) than conventional sarcopenia definitions. Individuals with low MSS demonstrated adverse metabolic profiles, including higher fasting glucose (101.0 ± 27.3 vs. 95.0 ± 18.7 mg/dL, p < 0.001), HbA1c (6.0% ± 0.9% vs. 5.8% ± 0.7%, p < 0.001) and HOMA‐IR (2.6 ± 2.2 vs. 1.8 ± 1.4, p < 0.001).

In adjusted models, high HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001) and elevated hsCRP (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.001) were strongly associated with low MSS.

Conclusions

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

Publication and source details

Original title: Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Wen‐Kai Chien; Wei‐Ju Lee; Chih‐Kuang Liang; Ko‐Han Yen; Li‐Ning Peng; Ming‐Hsien Lin; Ching‐Hui Loh; Fei‐Yuan Hsiao; Liang‐Kung Chen

Journal of Cachexia, Sarcopenia and Muscle · 2025

* Correspondence:
Wei‐Ju Lee (leewju@gmail.com)
Liang‐Kung Chen (lkchen2@vghtpe.gov.tw)
© 2025 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. National Science and Technology Council10.13039/501100020950 NSTC‐113‐2314‐B‐A49‐060NSTC 114‐2314‐B‐A49‐042 Taipei Veterans General Hospital10.13039/501100011912 114 VACS‐001

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:41:01.780422+00:00

DOI: 10.1002/jcsm.70078 · PMC12485295